These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose https://leaejqr823868.blog2freedom.com/39219832/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide